Jan 2026Hong Kong IPO filing (confidential) (next)
May 2026Hong Kong Polytechnic partnership: 60-participant pilot
Q4 2026Hong Kong IPO listing
Current obstacles
EEG signal degradation in real-world useMovement artifacts and variable electrode contact reduce signal quality outside lab settings; robust real-world performance remains a challenge.
Cost reduction to global accessibilityManufacturing cost limits widespread adoption in low-income regions; scaling production and reducing cost per unit is critical.
User training burdenNon-invasive BCIs require weeks of training for users to achieve fluent control; reducing this burden would speed adoption.
Physics limits
Non-invasive EEG signal amplitudeScalp-recorded signals are much weaker than invasive recordings, limiting the number of independently decodable channels.
Latency constraintsWireless transmission and AI decoding introduce latency; real-time responsiveness depends on algorithm speed and radio bandwidth.
Mechanical durabilityProsthetic durability and repair logistics are practical challenges for long-term deployment.
How it works
4 parts
Signal source
EEG or EMG input
Wearable EEG headband or implanted EMG sensors detect brain or muscle signals from the user's intent to move.
AI decoding
Neural network interpretation
Deep learning models decode brain/muscle patterns into commands for individual finger movements.
Motor control
Five independent actuators
Each finger is independently actuated, enabling complex fine-motor tasks like writing, typing, and gripping.
Real-time feedback
Sensory integration
Touch and proprioceptive feedback can be relayed back to the user for intuitive, closed-loop control.
BrainCo is a neurotechnology company headquartered in Hangzhou, China with a U.S. base in Massachusetts. Founded in 2015, it develops non-invasive brain-computer interfaces using EEG technology and AI-powered bionic prosthetics. The company filed for a Hong Kong IPO in January 2026.
BrainCo is one of Hangzhou's Hangzhou Six tech unicorns, competing with major neurotechnology firms globally.
Largest BCI funding round outside the U.S.: CNY 2B ($286M) in January 2026 co-led by IDG Capital.
Intelligent Bionic Hand in production at scale, with FDA listing and partnerships in Hong Kong providing prosthetics to 60 amputees.
